MELBOURNE, Feb 06, 2009 (AsiaPulse via COMTEX) -- BTAHY | Quote | Chart | News | PowerRating -- Biota Holdings Ltd (ASX:BTA) said on Friday that it had received written notification from global pharmaceuticals firm GlaxoSmithKline (GSK) that sales of the anti-flu drug Relenza amounted to A$20.8 million (US$13.53 million) and indicative royalties were A$1.46 million, for the three months ended December 31, 2008.
